Browse the evidence

GLP-1 receptor agonists (liraglutide, semaglutide) and GLP-1/GIP agonists (tirzepatide) produce significant weight loss in people with obesity without diabetes, but their use in postpartum women with previous gestational diabetes mellitus (GDM) is currently unsupported by evidence regarding safety, efficacy, and timing.

For women with a history of GDM, current guidelines recommend lifestyle modifications (diet and exercise) to reduce T2D risk, as pharmacological options like GLP-1 agonists lack safety and efficacy data for the postpartum period. While these drugs are effective for weight loss in the general obese population, they should not be used postpartum until further research clarifies their safety for mother and infant. Focus on sustainable lifestyle changes and regular monitoring.

Semaglutide 2.4 mg facilitates substantial, sustainable weight loss and improves cardiometabolic health by reducing 'food noise' and maladaptive eating behaviors.

Semaglutide 2.4 mg is an effective tool for reducing 'food noise' and enabling sustainable weight loss when lifestyle changes alone are insufficient. It works by altering hormonal signals related to appetite and satiety.

GLP-1RAs reduce emotional eating in the short term (3-6 months) by modulating reward processing, but this effect may not be long-lasting (12 months) and does not address underlying emotion regulation deficits.

GLP-1RAs like semaglutide can help reduce emotional eating for the first 3-6 months by changing how your brain responds to food rewards. However, this effect may fade after a year, and the medication does not fix the underlying emotional regulation skills. For lasting results, combine GLP-1RA treatment with emotion regulation therapies like CBT or DBT.

GLP-1 receptor agonists (e.g., semaglutide) and dual/triple agonists (e.g., tirzepatide) cause significant lean body mass loss (up to 40% of total weight loss), but this largely reflects reductions in non-contractile organs (liver, kidneys) rather than true skeletal muscle atrophy, with functional strength often preserved or improved.

If you are taking a GLP-1 drug like semaglutide, expect your total 'lean mass' number to drop significantly (up to 40% of weight lost). However, this is mostly water and organ mass (liver/kidneys), not your actual muscle fibers. Your strength likely stays the same or gets better because you are lighter. Focus on resistance training to maintain muscle quality, but do not panic about 'muscle wasting' as the primary driver of weight loss.

DJB implantation significantly improves glycemic control (HbA1c reduction) in patients with Type 2 Diabetes Mellitus.

For patients with Type 2 Diabetes, the DJB device can lower HbA1c levels from an average of 5.6% to 5.1% after one year. This improvement in blood sugar control is a key benefit alongside weight loss.

Personalized nutrition improves postprandial glycemic response (PPGR) compared to control diets, with a median mean difference of -14.85 mg/dLxh.

Personalized nutrition significantly improves postprandial glycemic response (PPGR) compared to standard diets. This means blood sugar spikes after meals are better managed with personalized advice.

Carriers of the T allele of the rs7903146 TCF7L2 polymorphism experience significantly greater reductions in body fat mass compared to CC homozygotes when treated with carbohydrate-restricted diet alone.

If you are undergoing dietary treatment for blood sugar issues, your genetic makeup (specifically the TCF7L2 gene) may determine how much body fat you lose. Those with the T allele tend to lose significantly more fat than those with the CC genotype. This suggests that personalized dietary advice based on genetics could optimize fat loss outcomes.

Homozgyous carriers of the C allele of the rs1042714 ADRB2 polymorphism experience significantly greater reductions in hip circumference compared to G allele carriers when treated with metformin and diet.

If you are taking metformin alongside a diet for blood sugar issues, your ADRB2 genetics may influence where you lose fat. Those with the CC genotype tend to reduce their hip circumference more significantly than those with the G allele. This suggests that personalized medical advice based on genetics could optimize body shape outcomes.

GLP-1 receptor agonists (semaglutide, tirzepatide) and Roux-en-Y gastric bypass (RYGB) surgery extend the duration of weight loss before reaching a plateau by weakening the physiological appetite feedback control circuit, whereas calorie restriction fails to weaken this circuit, leading to an earlier plateau.

If you are using GLP-1 medications or had bariatric surgery, your body's 'starvation signal' (appetite feedback) is chemically or surgically dampened, which is why you can lose weight for longer than diet-only approaches allow. Do not mistake the eventual plateau for failure; it is a sign that the feedback loop has stabilized. Calorie restriction alone fights this feedback loop directly, causing an earlier plateau.

GLP-1 agonist use (specifically semaglutide) is associated with a reduction in body mass index (from 34.1 ± 9 to 30.6 ± 6) and a decrease in smoking frequency/amount (by 14.4%) among users in Saudi Arabia.

If you are using GLP-1 agonists like semaglutide for weight loss, this study suggests you may also see a reduction in smoking frequency. However, be aware that cost and side effects are major reasons people stop taking the medication. To maintain weight loss, consistent use and healthy lifestyle habits (diet and exercise) are crucial, as obesity is a chronic condition requiring long-term management.

Semaglutide treatment is associated with a 26% lower risk of fractures compared to sleeve gastrectomy in adults with obesity.

If you are at high risk for fractures (e.g., older age, diabetes, history of falls) and need to lose weight, discuss semaglutide with your provider. This study suggests it may be safer for your bones than sleeve gastrectomy, offering a 26% lower fracture risk in a large real-world cohort. However, because this is observational data, ensure you monitor your bone health and nutrition regardless of the chosen path.

Enobosarm (3-6 mg/day) preserves total lean mass and reduces fat mass loss when co-administered with semaglutide for weight loss in older adults with overweight/obesity, without compromising overall body weight reduction.

If you are taking semaglutide for weight loss and are concerned about losing muscle, ask your doctor about adding enobosarm (3-6 mg daily). Recent Phase 2b data suggests this combination preserves lean mass and increases fat loss compared to semaglutide alone, without changing total weight loss. Note that this specific combination is still under regulatory review and not yet approved.

GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.

GLP-1 agonists like Liraglutide and Semaglutide are effective pharmacological treatments for obesity, producing significant weight loss (approx. 6-8%) when combined with lifestyle changes. While they show promise in improving gut microbiota in animal studies, clinical data on these specific changes is still emerging.

GLP-1 receptor agonists (GLP1-RAs) and dual GIP/GLP1-RAs (e.g., tirzepatide) significantly reduce body fat distribution (visceral, subcutaneous, epicardial) and anthropometric indices (BMI, waist circumference) in overweight or obese adults with or without type 2 diabetes.

If you are overweight or obese, especially with type 2 diabetes, GLP-1 receptor agonists are a proven pharmacological option to reduce body fat, including dangerous visceral fat, and improve metabolic health. These medications work by targeting hormones that regulate appetite and satiety. Consult a doctor to see if an injectable medication like semaglutide or tirzepatide is appropriate for your specific health profile and goals.

In patients with BMI ≥35 kg/m², improvements in glomerular filtration rate (GFR) are driven by the magnitude of weight loss and baseline renal function, regardless of whether the weight loss is achieved via metabolic and bariatric surgery (MBS) or high-dose GLP-1 agonist therapy.

For obese patients (BMI ≥35) concerned about kidney health, achieving significant weight loss is the key factor for improving glomerular filtration rate (GFR). Both high-dose GLP-1 agonists (like 3mg liraglutide) and bariatric surgery can improve kidney function to a similar degree, provided they result in substantial weight loss. The choice between medication and surgery should be based on patient preference and tolerability, as renal outcomes appear equivalent when weight loss is achieved.

In patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD), treatment with semaglutide 2.4 mg significantly reduces total annual medical costs and inpatient healthcare resource utilization compared to non-treated controls.

For patients with obesity and heart disease, using semaglutide 2.4 mg is associated with lower total medical bills over a year, primarily because it reduces the need for hospital stays. This suggests the drug can be cost-effective for this specific population by preventing expensive cardiovascular events.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss and modify inflammatory markers, suggesting potential oncological benefit, but high-quality data on cancer incidence is currently lacking.

GLP-1 agonists are effective for weight loss and may reduce cancer risk, but long-term cancer data is not yet available. They are a viable option for those who cannot undergo surgery.

GLP-1 receptor agonists (GLP-1RAs) are perceived by patients as effective for weight loss and appetite reduction, with positive treatment experiences correlating with therapy duration of 6 months or longer.

If you are considering GLP-1 medication, know that most patients report significant benefits for weight and appetite, especially if they stay on it for at least 6 months. Be prepared to discuss insurance coverage and side effects openly with your doctor to overcome common barriers.

Antiobesity medications (AOMs), including both injectable GLP-1 receptor agonists and oral formulations, produce similar weight loss outcomes and safety profiles in patients with celiac disease on a gluten-free diet as they do in patients without celiac disease.

If you have celiac disease and are on a gluten-free diet, antiobesity medications (like semaglutide or liraglutide) are likely to work for you just as well as they do for people without celiac disease. You do not need to avoid these medications due to fears about gut absorption, provided your celiac disease is managed with a strict gluten-free diet.

GLP-1 receptor agonists (exenatide, liraglutide) are effective for weight loss in patients with schizophrenia who are gaining weight due to antipsychotic medications (clozapine/olanzapine).

For patients with schizophrenia taking clozapine or olanzapine who experience significant weight gain, GLP-1 agonists (exenatide or liraglutide) are a promising treatment option. They effectively reduce weight gain (avg 3.71 kg difference) without interacting with the antipsychotic medications, avoiding the need to change psychiatric treatment.

GLP-1 receptor agonists (Liraglutide, Semaglutide) are effective and safe for treating obesity in children and adolescents, with FDA approval for Liraglutide in this population.

For children and adolescents with obesity, Liraglutide is an FDA-approved option. It helps reduce weight (avg 2.74 kg in trials) and improves HbA1c. Side effects are generally mild GI symptoms or minor hypoglycemia. It should be used alongside diet and exercise.

Pre-existing use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) is significantly associated with reduced weight loss in patients undergoing a Full Meal Replacement (FMR) intensive lifestyle intervention.

If you are currently taking a GLP-1 RA (like Ozempic or Wegovy) and start a strict meal replacement program, you might not lose as much weight as expected compared to those not on the medication. This does not mean the medication is ineffective, but its interaction with the FMR protocol may differ from standard expectations. Discuss this with your provider.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) reduce cancer risk in overweight/obese individuals primarily through sustained weight loss and secondarily through weight-loss-independent anti-inflammatory and metabolic mechanisms.

For individuals with obesity, GLP-1/GIP agonists (like semaglutide or tirzepatide) are more effective than diet alone for achieving sustained weight loss, which is linked to reduced cancer risk. These medications work by reducing hunger and improving metabolic health. While they require ongoing use and can be costly, they offer a clinically significant advantage over lifestyle changes alone for those who struggle with long-term adherence.

Dual GLP-1/Glucagon agonists (e.g., mazdutide, cotadutide, efinopegdutide) show promise for treating non-alcoholic steatohepatitis (NASH) and obesity, though with higher rates of gastrointestinal side effects compared to GLP-1 monotherapy.

For patients with obesity and non-alcoholic steatohepatitis (NASH), dual GLP-1/Glucagon agonists may offer a unique benefit by promoting liver fat oxidation. However, these drugs may cause more gastrointestinal side effects than standard GLP-1 drugs, so the trade-off between liver benefits and tolerability should be discussed with a doctor.